These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 35616682)

  • 21. Amivantamab: A Novel Advance in the Treatment of Non-small Cell Lung Cancer.
    Zavaleta-Monestel E; García-Montero J; Arguedas-Chacón S; Quesada-Villaseñor R; Barrantes-López M; Arroyo-Solís R; Zuñiga-Orlich CE
    Cureus; 2024 May; 16(5):e60851. PubMed ID: 38910714
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-small cell lung cancer with
    Kwon CS; Lin HM; Crossland V; Churchill EN; Curran E; Forsythe A; Tomaras D; Ou SI
    Curr Med Res Opin; 2022 Aug; 38(8):1341-1350. PubMed ID: 35621011
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients.
    Inoue A; Yoshida K; Morita S; Imamura F; Seto T; Okamoto I; Nakagawa K; Yamamoto N; Muto S; Fukuoka M
    Jpn J Clin Oncol; 2016 May; 46(5):462-7. PubMed ID: 26977054
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of Next-Generation EGFR-TKIs in Patients With Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.
    Qi YT; Hou Y; Qi LC
    Technol Cancer Res Treat; 2020; 19():1533033820940426. PubMed ID: 32723164
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
    Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.
    Wang M; Yang JC; Mitchell PL; Fang J; Camidge DR; Nian W; Chiu CH; Zhou J; Zhao Y; Su WC; Yang TY; Zhu VW; Millward M; Fan Y; Huang WT; Cheng Y; Jiang L; Brungs D; Bazhenova L; Lee CK; Gao B; Xu Y; Hsu WH; Zheng L; Jänne PA
    Cancer Discov; 2022 Jul; 12(7):1676-1689. PubMed ID: 35404393
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plain language summary of PAPILLON: amivantamab plus chemotherapy in untreated
    Sabari JK; Girard N; Mansfield AS; Sanborn RE; Agrawal T; Zhou C; Park K
    Future Oncol; 2024 Jul; ():1-13. PubMed ID: 39012623
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Advances in Treatment of Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations].
    Yang X; Zhao J
    Zhongguo Fei Ai Za Zhi; 2022 May; 25(5):337-350. PubMed ID: 35599009
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis.
    Vijayaraghavan S; Lipfert L; Chevalier K; Bushey BS; Henley B; Lenhart R; Sendecki J; Beqiri M; Millar HJ; Packman K; Lorenzi MV; Laquerre S; Moores SL
    Mol Cancer Ther; 2020 Oct; 19(10):2044-2056. PubMed ID: 32747419
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimizing diagnosis and treatment of EGFR exon 20 insertions mutant NSCLC.
    Passiglia F; Malapelle U; Normanno N; Pinto C
    Cancer Treat Rev; 2022 Sep; 109():102438. PubMed ID: 35882108
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy.
    Zhao Y; Wang H; He C
    J Cancer Res Clin Oncol; 2021 Dec; 147(12):3653-3664. PubMed ID: 34661758
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins.
    Remon J; Hendriks LEL; Cardona AF; Besse B
    Cancer Treat Rev; 2020 Nov; 90():102105. PubMed ID: 32979839
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
    Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
    BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lazertinib: on the Way to Its Throne.
    Lee J; Hong MH; Cho BC
    Yonsei Med J; 2022 Sep; 63(9):799-805. PubMed ID: 36031779
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New Strategies and Novel Combinations in EGFR TKI-Resistant Non-small Cell Lung Cancer.
    Girard N
    Curr Treat Options Oncol; 2022 Nov; 23(11):1626-1644. PubMed ID: 36242712
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Amivantamab in the Treatment of Metastatic NSCLC: Patient Selection and Special Considerations.
    Petrini I; Giaccone G
    Onco Targets Ther; 2022; 15():1197-1210. PubMed ID: 36246734
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FDA Approval Summary: Amivantamab for the Treatment of Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.
    Chon K; Larkins E; Chatterjee S; Mishra-Kalyani PS; Aungst S; Wearne E; Subramaniam S; Li Y; Liu J; Sun J; Charlab R; Zhao H; Saritas-Yildirim B; Bikkavilli RK; Ghosh S; Philip R; Beaver JA; Singh H
    Clin Cancer Res; 2023 Sep; 29(17):3262-3266. PubMed ID: 37022784
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Positive progress for non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: A novel targeted therapy option.
    Zhang W; Dong X
    J Oncol Pharm Pract; 2021 Dec; 27(8):2007-2009. PubMed ID: 34569378
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amivantamab (Rybrevant) for non-small cell lung cancer.
    Med Lett Drugs Ther; 2022 Nov; 64(1663):e184-e185. PubMed ID: 36384764
    [No Abstract]   [Full Text] [Related]  

  • 40. ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.
    Yoshida T; Song L; Bai Y; Kinose F; Li J; Ohaegbulam KC; Muñoz-Antonia T; Qu X; Eschrich S; Uramoto H; Tanaka F; Nasarre P; Gemmill RM; Roche J; Drabkin HA; Haura EB
    PLoS One; 2016; 11(1):e0147344. PubMed ID: 26789630
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.